Pfizer Late-Stage Meningitis B Drug Studies Meet Endpoints
August 21 2015 - 9:16AM
Dow Jones News
By Chelsey Dulaney
Pfizer Inc. said Friday that two late-stage studies for its
Trumenba meningitis B vaccine met their primary endpoint goals,
showing "robust immune responses" against some strains of
meningococcal disease.
One study included 3,600 healthy individuals ages 10 through 18,
while the other included 3,300 individuals aged 18 through 25.
Kathrin Jansen, senior vice president of vaccine research and
development for Pfizer, said the data supports vaccination of
adolescents and young adults to prevent meningococcal disease.
Trumenba was granted accelerated approval by the U.S. Food and
Drug Administration in October 2014 for 10-25-year-olds.
Pfizer has been focusing on building its meningitis vaccine
program lately.
In June, Pfizer agreed to buy two meningitis vaccines from
GlaxoSmithKline PLC for about $130 million. The acquisition
followed Pfizer's purchase last year of Baxter International Inc.'s
meningococcal disease vaccine NeisVac-C.
Write to Chelsey Dulaney at Chelsey.Dulaney@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
August 21, 2015 09:01 ET (13:01 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024
